写在卷首

初秋的凉爽很快就被深秋的寒意代替,时间很快就来到了2008年年底。在竞争日趋激烈和科学技术不断突飞猛进的大环境下,我们希望杂志在不断的探索中得到完善和提     

写在卷首

三月春意暖人心，“两会”精神催人进。国务院近期公布机构改革方案，国家食品药品监督管理局（下称药监局）并入卫生部，改由卫生部管理。卫生部将承担食品安全综合协调、组织查处食品安全重大事故的责任。药监局与卫生部下属的卫生监督局合并后，将集医政、药政监管于一体。     

写在卷首

2008年5月19日，世界肝炎联盟在全球正式启动为期5年的“世界肝炎日”活动，今年5月19日是第2个世界肝炎日。与去年一样，今年世界肝炎日的宣传活动主题依然是“我是第十二个吗？”意在向公众传递一个警示：即全球大约每12人中就有1例病毒性肝炎患者（包括乙型和丙型肝炎）。     

写在卷首

11月21日,我刊编缉部委员会2008年度会议顺利召开.窗外是初冬暖暖的阳光,窗内则是与会编委热烈的讨论.各位专家在肯定编辑部工作的同时也提出了很多中肯的批评和建议,更为我刊念后的发展积极出谋划策.     

写在卷首

随着人均寿命的日益延长及各种检查和诊断技术的快速提高,泌尿生殖系统肿瘤的发病率呈增高趋势,已成为危害人体健康的重要疾病.常见的男性泌尿生殖系统恶性肿瘤包括前列腺癌、膀胱癌及肾癌等.针对其研制的新药及不断涌现的基础和临床最新成就,均为攻克泌尿生殖系统肿瘤带来新的希望.     

写在卷首

2009年11月20日,本刊2009年度全体编委会议顺利召开,这也是本刊入选中国科技核心期刊后的首次编委全体会议.与会编委积极建言,为本刊的进一步发展出谋划策,虽然阴雨绵绵,但室内热烈的讨论气氛温暖着我们的心.     

写在卷首

抗震救灾工作已进入灾后恢复重建阶段.震区灾后重建工作启动后,国家成立了专门的重建规划组,向社会公众广泛征求意见.为妇女权益工作的民间组织和个人,提交并发表了<关注灾区妇女的需求与权利>建议书,恳请有关部门在赈灾和重建工作中保障妇女儿童的权益.灾后保护弱势人群,这是重建工作的议题之一.     

写在卷首

备受国内外血液学界瞩目的第50届美国血液学年会（ASH）于2009年12月在美国加州旧金山举行。本次年会适逢ASH50周年庆典，通过回顾历史，展望未来，为今后的血液学研究工作指明了方向。相信在不久的将来，血液病学领域必将有更多的研究成果面世，造福广大患者。     

写在卷首

早春三月,虽然春寒料峭,但枝头一簇簇绽放的梅花已经让我们欣喜地感受到春的气息.春天是朝气蓬勃的,也是充满希望的,衷心祝愿每-位读者朋友明天会更美好. 心脑血管疾病的防治已成为全社会共同关注的问题.调脂药物在心脑血管疾病的防治中占据重要地位.本期医药专论的主题即为调脂     

写在卷首

近日，国家食品药品监管局药品评价中心发布《克林霉素注射剂安全性评价报告》，报告显示，由于不合理用药等现象，导致克林霉素注射剂的不良反应问题严重，不良反应涉及全身性损害、呼吸系统损害和泌尿系统损害等。任何药物都有不良反应，只是程度不同而已。至今无任何不良反应的药物尚未见报道，关键是如何合理用药。因此，在治疗疾病的同时，除药物正常的不良反应外，在使用时须特别注意用药剂量、适应证、药物相互作用和用药禁忌等，尤其是针对儿童，老年人，孕期、哺乳期妇女等特殊人群。     

Editorial

A themed section in this issue of Br J Pharmacol, on ‘Advances in Nutritional Pharmacology’, provides a valuable and timely update on progress in this area.The value of dietary components to improvement in health and, particularly, to prevention of cardiovascular disease and cancer, is frequently reported in the media and therefore often captures the attention of the wider public. Understanding the pharmacological mechanisms by which nutritional elements confer their health benefits enables us to keep the public informed, but also aids in the identification of new targets for drug development. In recent years there has been significant progress in this field.Four rapidly developing areas are reviewed. Vosper (2009) covers the identification of a receptor for niacin and the subsequent development of selective agonists as lipid lowering agents. Wu-Wong (2009) describes the development of new Vitamin D analogues for the treatment of cardiovascular disease. de Roos et al. (2009) provide detailed insight into how omega-3 fatty acids, also known as longchain n-3 polyunsaturated fatty acids (PUFAs) protect against cardiovascular disease. Zhou et al. (2009) cover the mechanisms underlying the beneficial effects of resveretrol in protection against cancer.These reviews are complimented by three key original articles focusing on endogenous mechanisms of weight control involving endocannabinoids (Izzo et al., 2009), a circulating protein, the soluble leptin receptor (Zhang & Scarpace, 2009) and a treatment, zinc plus cyclo-(His-Pro) (CHP), known to increase insulin metabolism (Song et al., 2009).The value of dietary components to improvement in health and, particularly, to prevention of cardiovascular disease and cancer, is frequently reported in the media and therefore often captures the attention of the wider public. Understanding the pharmacological mechanisms by which nutritional elements confer their health benefits enables us to keep the public informed, but also aids in the identification of new targets for drug development. In recent years there has been significant progress in this field.A themed section in this issue of Br J Pharmacol, on ‘Advances in Nutritional Pharmacology’, edited by Cherry Wainwright, aims to provide a valuable and timely update on progress in this area.This issue includes several reviews that provide an update in four rapidly developing areas. Vosper (2009) has written a narrative tracking the research that led to the identification of a receptor for niacin and the subsequent development of selective agonists as lipid lowering agents. Within this review, the benefits and pitfalls of niacin receptor agonists are discussed, alongside a consideration of the impact of blocking their undesirable effects, such as skin flushing. Two further reviews describe the development of new Vitamin D analogues for the treatment of cardiovascular disease(Wu-Wong, 2009) and provide detailed insight into how omega-3 fatty acids, also known as longchain n-3 polyunsaturated fatty acids (PUFAs) protect against cardiovascular disease (de Roos et al., 2009). The fourth review provides greater understanding of the mechanisms underlying the beneficial effects of resveretrol in protection against cancer (Zhou, 2009).These reviews are complimented by three key original articles focusing on endogenous mechanisms of weight control. In an elegant study in lean and fatty mice with diet induced obesity, Izzo et al. (2009) have provided evidence to support the idea that dysregulation of peripheral endocannabinoids can contribute to obesity. In a further in vivo study, direct evidence is provided that a circulating protein, the soluble leptin receptor, may play a regulatory role in energy homeostasis and weight gain by neutralizing leptin (Zhang & Scarpace, 2009). Finally Song et al. (2009) have demonstrated in both diabetic and non-diabetic overweight aged rats that zinc plus cyclo-(His-Pro) (CHP), a treatment known to increase insulin metabolism, improves weight control through reducing food intake and altering the balance between plasma leptin and adiponectin levels, suggesting this may be a possible treatment for overweight and obese patients.     

Editorial

This themed issue of the British Journal of Pharmacology stems from the 7th in the series of meetings on the Molecular Pharmacology of G Protein-Coupled Receptors (MPGPCR) held at the Monash Institute of Pharmaceutical Sciences in Melbourne Australia from the 6th–8th December 2012.Linked ArticlesThis article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-5     

Editorial

Cell movement is a fundamental process of normal cellular physiology and pathophysiology. Abnormal regulation of cell migration is a common denominator of many medical disorders, including cancer metastasis, autoimmune disease and inflammation. Increased interest in the targeting of cell migration and invasion, which has potential for therapeutic intervention in many diseases are behind this special themed issue. Thus, the focus of this issue is centred on the control of cellular cytoskeletal dynamics and cellular or tissue microenvironment sensors. Novel therapeutic opportunities targeting regulation of cell migration are discussed including the emerging roles of tetraspanins, phosphoinositides, transient receptor potential cation channels, stromal interaction molecules and calcium release-activated calcium modulators. Better understanding of these regulatory factors will hopefully bring greater attention to strategically targeting aberrant cell migration, which has many therapeutic implications for common human diseases.

Linked Articles

This article is part of a themed section on Cytoskeleton, Extracellular Matrix, Cell Migration, Wound Healing and Related Topics. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-24The regulation of cell migration is complex and involves sequential chains of events in both normal and pathological conditions. This complexity has proven to be a challenge in therapeutic development but at the same time offers interventional opportunities. Cytoskeletal dynamics involves various regulatory processes, which offers several potential intervention points for anti-migration drugs. In this issue, leading scientists in the area of inflammation, wound healing and tumour biology have contributed an overview of cell migration and perspectives on the clinical application of anti-migration therapeutics. There is discussion of new and/or emerging roles of novel therapeutic interventions targeting cytoskeletal dynamics such as membrane lipids, the Ras superfamily of small GTPase proteins, transmembrane spanning tetraspanins, calcium sensors and ion channels.In cancer, cell migration is required for local invasion, angiogenesis and metastasis, which are common characteristics for all cancers, as reviewed by Hanahan and Weinberg 2011. Cancer morbidity and mortality are largely related to the spread of the primary, localized tumour to adjacent and distant sites. Appropriate management and treatment decisions for metastatic disease are crucial and are better informed by greater understanding of the metastatic process. There are common events that occur during metastasis: dissociation from the primary tumour mass, reorganization/remodelling of extracellular matrix, cell migration, recognition and traversal of endothelial cells into the vascular circulation and lodgement and proliferation within ectopic stroma. One of the key and initial events is the increased capability of cancer cells to move through tissue planes and escaping normal physiological constraints. The first of the anti-migration class of inhibitors to be approved for multiple sclerosis and Crohn''s disease is natalizumab (Selewski et al., 2010); the migration-inhibitory mode of action of natalizumab is through its antibody-tail binding to α4 integrin on lymphocytes preventing its binding to endothelial cells, hence transmigration across vascular endothelium (Yednock et al., 1992; Tubridy et al., 1999). Detchokul et al. (2014) have also reviewed the emerging role of members of the transmembrane-4-superfamily (or tetraspanins) in the regulation of cancer migratory processes and the potential of therapeutic targets against tetraspanins and their binding partners, including integrins, matrix metalloproteinases, EWI proteins (a cell surface immunoglobulin SF protein) and E-cadherin.The cellular cytoskeleton is at the heart of the cell migration process in both normal and pathological conditions (Fletcher and Mullins, 2014; Stricker et al., 2010; Rottner and Stradal, 2011; Ratheesh and Yap, 2012). An active change in cancer cytoskeletal dynamics results in manipulation of plasma membrane and cellular balance between cellular adhesion and motility which in turn determines cancer cell movement. In this issue, Fife et al. (2014) discuss the role of the cytoskeletal proteins, namely actins, intermediate filaments and microtubules, in cancer migration and metastasis. In particular, the role of microtubules in the regulation of migration, invasion and metastasis in various cancers was highlighted. Increasing evidence reveal that microtubule and actin cytoskeletal dynamics are both controlled by Rho family of GTPases (Rho-GTPases). Microtubules, in turn, are able to mediate Rho-GTPases. Crosstalk between actin and microtubules does occur, which furthermore underscores the regulatory role of microtubule systems to the actin cytoskeletal regulation. This new knowledge opens doors to discovery of new biomarkers and therapeutic targets for cancer migration and metastasis. Biro et al. (2014) have also given a comprehensive review on the regulatory pathways of actomyosin dynamics in immune cell migration. They draw attention to the therapeutic intervention points from the downstream signalling in Rho-GTPase pathways such as Rho kinase (ROCK), Cdc42 and Rac. Increasing understanding of the control of these molecules has led to the development of pharmaceutical compounds acting against these molecules.Another regulatory mechanism of the actin cytoskeleton dynamics is via actin binding proteins and membrane lipids, as reviewed by Wu et al. (2014). The PI3K signalling pathway (i.e. PI3K–AKT–mTOR) is well-recognized as dysregulated in many cancers, including breast cancer, multiple myeloma, leukaemia, lymphoma (Samuels and Waldman, 2010; Jensen et al., 2012) and inflammatory respiratory diseases (Ito et al., 2007; Doukas et al., 2009). Many candidate inhibitors have been developed to counteract members of this pathway (Liu et al., 2009; Cheng et al., 2014; Marcias-Perez and Flinn, 2013; Yang et al., 2013). Nevertheless, most single-agent cancer trials did not yield anticipated results (Fruman and Rommel, 2014), leading to further searches for more specific targeting such as different isoforms of PI3K (Ameriks and Venable, 2009). Chen et al., in this issue, has reviewed the current understanding of metabolism of phosphoinositides in particular PI(4,5)P₂ and PI(3,4,5)P_2, and discussed their multiple involvements in the regulation of actin binding proteins. These multidimensional roles of phosphoinositides may be indicative of challenging outcomes for targeting the PI3K signalling pathway, as seen in early phase clinical trials.Earlier this year, the BJP published a very informative themed issue on transient receptor potential (TRP) channel superfamily (Holzer and Izzo, 2014) bringing forth their importance in many pathological conditions, namely pain sensation, bladder dysfunction and pulmonary diseases. In the current issue, Nielsen et al. (2014) comprehensively review the role of TRP channels and functional partners Ca²⁺ sensitive stromal interaction molecule (STIM)/calcium release-activated calcium modulator (ORAI) proteins in cancer migration and metastasis. Increasing evidence has been found of the role stromal cells play in cancer metastasis; TRP channels and STIM/ORAI proteins have a potential role in the regulation of crosstalk between cancer and stromal cells and thereby influence the migration of both cell types. Besides being cellular environmental sensors, TRP channels are linked to the actomyosin cytoskeleton. This review summarizes their role as sensors and effectors in cancer migration and metastasis and detailed subtype expression in various cancers was also summarized, supporting a potential role of these proteins as drug targets.Taken together, these reviews represent for the reader a sample of active research in the cell migration field, the hope being that greater mechanistic understanding might now lead to novel therapeutic approaches to common conditions such as cancer and inflammatory disorders.